JP2008526935A - 創傷治癒のためのｉｌ−１０関連ペプチド - Google Patents
創傷治癒のためのｉｌ−１０関連ペプチド Download PDFInfo
- Publication number
- JP2008526935A JP2008526935A JP2007550830A JP2007550830A JP2008526935A JP 2008526935 A JP2008526935 A JP 2008526935A JP 2007550830 A JP2007550830 A JP 2007550830A JP 2007550830 A JP2007550830 A JP 2007550830A JP 2008526935 A JP2008526935 A JP 2008526935A
- Authority
- JP
- Japan
- Prior art keywords
- wound
- use according
- drug
- scar
- scarring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000029663 wound healing Effects 0.000 title claims abstract description 117
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 103
- 102000004196 processed proteins & peptides Human genes 0.000 title description 31
- 102000003814 Interleukin-10 Human genes 0.000 title description 9
- 108090000174 Interleukin-10 Proteins 0.000 title description 9
- 230000037390 scarring Effects 0.000 claims abstract description 139
- 230000002829 reductive effect Effects 0.000 claims abstract description 71
- 208000027418 Wounds and injury Diseases 0.000 claims description 316
- 206010052428 Wound Diseases 0.000 claims description 301
- 231100000241 scar Toxicity 0.000 claims description 237
- 239000003814 drug Substances 0.000 claims description 158
- 229940079593 drug Drugs 0.000 claims description 150
- 230000035876 healing Effects 0.000 claims description 61
- 230000001737 promoting effect Effects 0.000 claims description 26
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 22
- 230000001684 chronic effect Effects 0.000 claims description 20
- 230000001965 increasing effect Effects 0.000 claims description 16
- 230000001575 pathological effect Effects 0.000 claims description 14
- 230000028709 inflammatory response Effects 0.000 claims description 12
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 206010072170 Skin wound Diseases 0.000 claims description 6
- 208000002847 Surgical Wound Diseases 0.000 claims description 6
- 238000012937 correction Methods 0.000 claims description 6
- 108010034537 alanyl-tyrosyl-methionyl-threonyl-methionyl-lysyl-isoleucyl-arginyl-asparagine Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000002316 cosmetic surgery Methods 0.000 claims description 2
- GTORPNRZTBKYJB-AIEIIIEWSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]hexanoyl Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=C(O)C=C1 GTORPNRZTBKYJB-AIEIIIEWSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 208000032544 Cicatrix Diseases 0.000 description 90
- 230000037387 scars Effects 0.000 description 90
- 238000000034 method Methods 0.000 description 88
- 210000003491 skin Anatomy 0.000 description 67
- 239000003795 chemical substances by application Substances 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- 230000009467 reduction Effects 0.000 description 29
- 238000011282 treatment Methods 0.000 description 25
- 239000000203 mixture Substances 0.000 description 24
- 239000000546 pharmaceutical excipient Substances 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 23
- 230000006378 damage Effects 0.000 description 22
- 230000036573 scar formation Effects 0.000 description 22
- 239000000835 fiber Substances 0.000 description 21
- 230000004044 response Effects 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 20
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 20
- 210000002744 extracellular matrix Anatomy 0.000 description 20
- 208000014674 injury Diseases 0.000 description 20
- 230000006872 improvement Effects 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 230000000007 visual effect Effects 0.000 description 15
- 230000001969 hypertrophic effect Effects 0.000 description 13
- 238000007431 microscopic evaluation Methods 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 230000002159 abnormal effect Effects 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 9
- 238000007619 statistical method Methods 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 208000002260 Keloid Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 229940076144 interleukin-10 Drugs 0.000 description 8
- 210000001117 keloid Anatomy 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000037311 normal skin Effects 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 108010043958 Peptoids Proteins 0.000 description 6
- 230000001133 acceleration Effects 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 238000010191 image analysis Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 210000005081 epithelial layer Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 208000037997 venous disease Diseases 0.000 description 4
- 241000283086 Equidae Species 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003810 hyperpigmentation Effects 0.000 description 3
- 208000000069 hyperpigmentation Diseases 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 210000004303 peritoneum Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000012439 solid excipient Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 208000003367 Hypopigmentation Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 206010039580 Scar Diseases 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000037313 granulation tissue formation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000003425 hypopigmentation Effects 0.000 description 2
- 208000011379 keloid formation Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000005226 mechanical processes and functions Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000001314 profilometry Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000037309 reepithelialization Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000007794 visualization technique Methods 0.000 description 2
- IEIMRKVTGUNYPS-RSLQBAFYSA-N (2S)-3-hydroxypyrrolidine-2-carboxylic acid (2S)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CN[C@H](C(O)=O)C1.OC1CCN[C@@H]1C(O)=O IEIMRKVTGUNYPS-RSLQBAFYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- NDDZMHYTLXPYHA-UHFFFAOYSA-N 2-aminohexanedioic acid;3-aminohexanedioic acid Chemical compound OC(=O)CC(N)CCC(O)=O.OC(=O)C(N)CCCC(O)=O NDDZMHYTLXPYHA-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 208000012260 Accidental injury Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- -1 L-form amino acids Chemical class 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- AWMNVAXPRNBKRQ-UHFFFAOYSA-N N1CCCCC1.NCCCC(=O)O.NC(C(=O)O)CC.NCCC(=O)O Chemical compound N1CCCCC1.NCCCC(=O)O.NC(C(=O)O)CC.NCCC(=O)O AWMNVAXPRNBKRQ-UHFFFAOYSA-N 0.000 description 1
- ICLAYCQSFANRPO-UHFFFAOYSA-N NCC(C(=O)O)C.NC(C(=O)O)(C)C.NC(C(=O)O)CCCCC.NCCCCCC(=O)O Chemical compound NCC(C(=O)O)C.NC(C(=O)O)(C)C.NC(C(=O)O)CCCCC.NCCCCCC(=O)O ICLAYCQSFANRPO-UHFFFAOYSA-N 0.000 description 1
- VBCSVOLTQVIQQJ-PWLGDCFPSA-N N[C@@H](CC[C@@H](O)CN)C(=O)O.C(C)N[C@@H](CC(N)=O)C(=O)O.C(C)NCC(=O)O.NC(C(=O)O)CN Chemical compound N[C@@H](CC[C@@H](O)CN)C(=O)O.C(C)N[C@@H](CC(N)=O)C(=O)O.C(C)NCC(=O)O.NC(C(=O)O)CN VBCSVOLTQVIQQJ-PWLGDCFPSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000052620 human IL10 Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000009520 penetrating brain damage Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- YSMODUONRAFBET-WHFBIAKZSA-N threo-5-hydroxy-L-lysine Chemical compound NC[C@@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-WHFBIAKZSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0500643.2A GB0500643D0 (en) | 2005-01-13 | 2005-01-13 | Medicaments |
| PCT/GB2006/000051 WO2006075138A2 (en) | 2005-01-13 | 2006-01-06 | Il-10 related peptides for wound healing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012165481A Division JP2012211185A (ja) | 2005-01-13 | 2012-07-26 | 創傷治癒のためのｉｌ−１０関連ペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008526935A true JP2008526935A (ja) | 2008-07-24 |
| JP2008526935A5 JP2008526935A5 (enExample) | 2009-02-26 |
Family
ID=34224534
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007550830A Pending JP2008526935A (ja) | 2005-01-13 | 2006-01-06 | 創傷治癒のためのｉｌ−１０関連ペプチド |
| JP2012165481A Pending JP2012211185A (ja) | 2005-01-13 | 2012-07-26 | 創傷治癒のためのｉｌ−１０関連ペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012165481A Pending JP2012211185A (ja) | 2005-01-13 | 2012-07-26 | 創傷治癒のためのｉｌ−１０関連ペプチド |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20080139478A1 (enExample) |
| EP (2) | EP2332566A1 (enExample) |
| JP (2) | JP2008526935A (enExample) |
| AU (1) | AU2006205696C1 (enExample) |
| CA (1) | CA2594798A1 (enExample) |
| GB (1) | GB0500643D0 (enExample) |
| WO (1) | WO2006075138A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0500643D0 (en) | 2005-01-13 | 2005-02-23 | Renovo Ltd | Medicaments |
| RU2542471C2 (ru) * | 2006-11-15 | 2015-02-20 | Коуда Терапьютикс, Инк. | Улучшенные способы и композиции для заживления ран |
| EP2451780B1 (en) | 2009-07-06 | 2013-06-19 | AstraZeneca AB | Intermediates and processes for the preparation of 4-(acetylamino))-3-[(4-chloro-phenyl)thio]-2-methyl-1h-indole-1-acetic acid |
| EP2691515A2 (en) * | 2011-03-31 | 2014-02-05 | President and Fellows of Harvard College | A unique population of regulatory t cells that regulate tissue regeneration and wound healing |
| US20160287744A1 (en) | 2012-11-14 | 2016-10-06 | 3-D Matrix Ltd. | Vascular embolic system |
| CA2905182A1 (en) * | 2013-03-14 | 2014-09-18 | 3-D Matrix, Ltd. | Materials for gastrointestinal obstruction prevention |
| EP2986306A4 (en) | 2013-04-18 | 2016-12-07 | Armo Biosciences Inc | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING |
| CA2914837A1 (en) | 2013-06-17 | 2014-12-24 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| US10098929B2 (en) | 2013-08-02 | 2018-10-16 | Children's Hospital Medical Center | Method of reducing scar formation in healing of dermal wounds by administering interleukin-10 and hyaluronan |
| US10010588B2 (en) | 2013-08-30 | 2018-07-03 | Armo Biosciences, Inc. | Methods of using pegylated interleukin-10 for treating hyperlipidemia |
| KR20160079114A (ko) | 2013-11-11 | 2016-07-05 | 아르모 바이오사이언시스 인코포레이티드 | 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법 |
| WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| EP3206713A4 (en) | 2014-10-14 | 2018-06-27 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| AU2015336101A1 (en) | 2014-10-22 | 2017-04-20 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| WO2016191587A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| CA2995120A1 (en) | 2015-08-25 | 2017-03-02 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10502249A (ja) * | 1994-07-05 | 1998-03-03 | スティーノ・リサーチ・グループ・アクティーゼルスカブ | 免疫調節剤 |
| JPH11510505A (ja) * | 1995-08-09 | 1999-09-14 | ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター | Ｉｌ−１０含有医薬組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6217857B1 (en) * | 1989-06-28 | 2001-04-17 | Schering Corporation | Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof |
| WO1997026278A1 (en) * | 1996-01-18 | 1997-07-24 | Steeno Research Group A/S | Synthetic il-10 analogues |
| GB0500643D0 (en) | 2005-01-13 | 2005-02-23 | Renovo Ltd | Medicaments |
-
2005
- 2005-01-13 GB GBGB0500643.2A patent/GB0500643D0/en not_active Ceased
-
2006
- 2006-01-06 EP EP10182870A patent/EP2332566A1/en not_active Withdrawn
- 2006-01-06 EP EP06701354.0A patent/EP1858544B1/en not_active Expired - Lifetime
- 2006-01-06 US US11/795,135 patent/US20080139478A1/en not_active Abandoned
- 2006-01-06 CA CA002594798A patent/CA2594798A1/en not_active Abandoned
- 2006-01-06 AU AU2006205696A patent/AU2006205696C1/en not_active Ceased
- 2006-01-06 JP JP2007550830A patent/JP2008526935A/ja active Pending
- 2006-01-06 WO PCT/GB2006/000051 patent/WO2006075138A2/en not_active Ceased
-
2011
- 2011-10-07 US US13/317,030 patent/US20120238505A1/en not_active Abandoned
-
2012
- 2012-07-26 JP JP2012165481A patent/JP2012211185A/ja active Pending
-
2014
- 2014-09-16 US US14/487,838 patent/US20150218222A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10502249A (ja) * | 1994-07-05 | 1998-03-03 | スティーノ・リサーチ・グループ・アクティーゼルスカブ | 免疫調節剤 |
| JPH11510505A (ja) * | 1995-08-09 | 1999-09-14 | ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター | Ｉｌ−１０含有医薬組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006205696A1 (en) | 2006-07-20 |
| HK1105366A1 (en) | 2008-02-15 |
| WO2006075138A2 (en) | 2006-07-20 |
| US20120238505A1 (en) | 2012-09-20 |
| EP2332566A1 (en) | 2011-06-15 |
| EP1858544A2 (en) | 2007-11-28 |
| CA2594798A1 (en) | 2006-07-20 |
| US20150218222A1 (en) | 2015-08-06 |
| WO2006075138A3 (en) | 2006-10-19 |
| JP2012211185A (ja) | 2012-11-01 |
| GB0500643D0 (en) | 2005-02-23 |
| AU2006205696C1 (en) | 2012-01-19 |
| US20080139478A1 (en) | 2008-06-12 |
| EP1858544B1 (en) | 2014-03-05 |
| AU2006205696B2 (en) | 2011-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012211185A (ja) | 創傷治癒のためのｉｌ−１０関連ペプチド | |
| US20100266532A1 (en) | Methods for inhibiting scarring | |
| JP2001511797A (ja) | 創傷の治癒 | |
| JP2025138709A (ja) | 合成ペプチドとその応用 | |
| KR20080031405A (ko) | 상피 재생의 촉진 | |
| US20020103112A1 (en) | Wound healing and treatment of fibrosis | |
| US20110212897A1 (en) | Wnt3a for inhibition of scarring | |
| US20100261659A1 (en) | Secreted frizzled related protein 3 for use in the inhibition of scarring | |
| US20100137201A1 (en) | Medicaments | |
| WO2015114324A1 (en) | Transmucosal and transepithelial drug delivery system | |
| JP2011522020A (ja) | 瘢痕を抑制する薬剤および方法 | |
| JP2010535184A (ja) | 非眼瘢痕の抑制に使用できる薬剤および方法 | |
| HK1105366B (en) | Il-10 related peptides for wound healing | |
| HK1158509A (en) | Il-10 related peptides for wound healing | |
| CA2733797A1 (en) | Methods for inhibition of scarring | |
| CA2733794A1 (en) | Methods for the inhibition of scarring | |
| WO2008125864A1 (en) | Sfrp3 for use in accelerating wound healing | |
| HK1025732B (en) | Wound healing and treatment of fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110801 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111027 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111104 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111130 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120201 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120326 |